TDA's analysis looks roughly like mine.
If you simplify away the generic share of market, share of profits, etc. a rough guide is that Alchemia can conservatively expect to earn around 10% of total US Arixtra/fondaparinux sales.
That needs to be risk weighted. It's possible the Dr Reddy/Alchemia generic will fail to achieve approval at all, or be blocked by patent litigation by GSK. It's possible that there will be long delays before approval.
- Forums
- ASX - By Stock
- TSN
- once it hits the market
once it hits the market, page-19
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online